anlotinib hydrochloride + PD1 inhibitor + gemcitabine + cisplatin

This is a combination regimen consisting of four agents: - **Anlotinib hydrochloride** is a multi-targeted small molecule tyrosine kinase inhibitor that inhibits angiogenesis and tumor cell proliferation by targeting receptors such as VEGFR, FGFR, PDGFR, and c-Kit[1][2][5]. - **PD1 inhibitors** (such as toripalimab or other anti-PD-1 monoclonal antibodies) are immune checkpoint inhibitors that block the programmed death 1 (PD-1) receptor on T cells, thereby enhancing antitumor immune responses by preventing tumor-induced T cell inactivation[6][8][10]. - **Gemcitabine** is a nucleoside analog chemotherapeutic agent that inhibits DNA synthesis and induces apoptosis in rapidly dividing cells. - **Cisplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis. This combination leverages antiangiogenic therapy (anlotinib), immunotherapy (PD1 blockade), and cytotoxic chemotherapy (gemcitabine plus cisplatin). It has been investigated primarily for advanced solid tumors including biliary tract cancer, non-small cell lung cancer, sarcomas, and other malignancies. The rationale for this regimen is to combine direct cytotoxic effects with modulation of the tumor microenvironment to enhance immune-mediated antitumor activity[1][5].

Other names

anlotinib hydrochloride + PD1 inhibitor + gemcitabine + cisplatin